Video

BTK Inhibitor Use Proves Beneficial in Mantle Cell Lymphoma Treatment

Author(s):

Typically, the longer a patient with cancer is exposed to a drug the more side effects they experience, but in the case of Imbruvica, the opposite appears to be true for patients with MCL.

Contrary to what is sometimes seen with chemotherapy, research being presented at the 2019 American Society of Hematology (ASH) Annual Meeting has found that BTK inhibitors such as Imbruvica (ibrutinib) could provide better responses in patients with mantle cell lymphoma (MCL), even after more than seven years of treatment.

Typically, patients experience greater side effects the longer they are exposed to a drug, but according to Dr. Simon Rule, a professor of hematology at Plymouth University, many patients saw no new toxicities with extended use of Imbruvica.

Transcription:

What we did was just a further follow up on a group of patients that we’ve been looking at for a while now. It’s three trials of patients receiving single-agent ibrutinib, and basically, it’s just long-term follow up to see whether with longer exposure to a drug, you’re developing side effects or whether the efficacy is still there. It’s basically an additional safety analysis.

What we found was that a portion of patients still remain on the drug, with a seven-and-a-half-year follow up, and there’s no emergence of new toxicity, which is very encouraging. But perhaps the most important bit of the analysis was, for the first time, we looked at how response to ibrutinib compared with prior therapies.

With MCL, when you use chemotherapy, each time you use a different chemotherapy, you get less of a response. This is a common thing you see with lymphomas. But with MCL, when you use ibrutinib, what we find is that the ibrutinib response is generally better than the prior chemotherapy. In one group, it’s spectacularly better, and that’s the patients that get the most benefit from the chemotherapy.

So that’s the group where people would be more inclined to use chemotherapy again, but actually that group gets the most benefit (from ibrutinib). In fact, the average benefit is more than a year from the second therapy compared with the first. This is against what one normally finds with chemotherapy. So, it just further encourages the use of these drugs earlier in the treatment paradigm.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.